Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations
05 déc. 2017 07h30 HE
|
Actinium Pharmaceuticals
Phase 2 clinical trial planned for 2018, Actimab-MDS intended to be a bridge to a bone marrow transplant, the only curative treatment option for patients with myelodysplastic syndromeTrial principal...
Actinium Pharmaceuticals Announces Multiple Posters/Abstracts Accepted for 59th Annual American Society of Hematology Meeting Highlighting Company’s Drug Candidates and Technology Platform
01 nov. 2017 09h05 HE
|
Actinium Pharmaceuticals
Data from ongoing Actimab-A Phase 2 clinical trial highlighting efficacy, safety profile and clinical strategy as a single agent targeting CD33 in patients with AMLStudies highlighting enhanced...
Actinium Pharmaceuticals Announces Activation of Fifteenth Clinical Trial Site in the Phase 3 SIERRA Trial for Iomab-B
25 oct. 2017 07h30 HE
|
Actinium Pharmaceuticals
- Current clinical trial sites represent approximately one third of bone marrow transplant volume in the U.S. - Actinium to provide update on SIERRA clinical trial by year-end NEW YORK, Oct. 25,...
Actinium Pharmaceuticals to Present at BIO Investor Forum
16 oct. 2017 07h30 HE
|
Actinium Pharmaceuticals
- Actinium to present on Tuesday, October 17th at 3 PM PT NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...
Actinium Pharmaceuticals Provides Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid Leukemia
04 oct. 2017 07h30 HE
|
Actinium Pharmaceuticals
- Phase 2 clinical trial is currently active at 16 clinical trial sites in the United States, surpassing the 10 clinical trial sites that were planned for the trial - Actinium affirms guidance for...
Actinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council Meeting
20 sept. 2017 07h30 HE
|
Actinium Pharmaceuticals
- Actinium is now a member of the ASBMT™ Corporate Council - Two day event focused on facilitating dialogue aimed at advancing the field of bone marrow transplantation and cellular therapy NEW YORK,...
Actinium to Present at The Rodman & Renshaw 19th Annual Global Investment Conference
06 sept. 2017 16h05 HE
|
Actinium Pharmaceuticals
NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Boston Oncology Insights Summit on August 16-17, 2017
09 août 2017 07h30 HE
|
Actinium Pharmaceuticals
NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Highlighting Accomplishments and Significant Value Enumerating Catalysts Over the Coming Quarters
15 juin 2017 08h30 HE
|
Actinium Pharmaceuticals
- Iomab-B Phase 3 SIERRA trial enrollment is accelerating as the number of clinical trial sites increase, competitive position as only induction and conditioning regimen remains unchallenged -...
Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
12 juin 2017 07h00 HE
|
Actinium Pharmaceuticals
Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in...